Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05893888
Other study ID # CLN-004
Secondary ID 1R44CA272095-01
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date October 16, 2023
Est. completion date October 2026

Study information

Verified date January 2024
Source Privo Technologies
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PRV211 is a sterilized nano engineered delivery system intended for intraoperative chemotherapy treatment for all solid tumor surgeries immediately following surgical excision. The goal is to treat the tumor bed locally, eliminating any remaining micro metastases or close margins that are unable to be fully resected while avoiding system circulation. This study will enroll up to 40 subjects. In this study both safety and efficacy will be evaluated. All subjects will be monitored for possible DLTs.


Description:

Methodology: This is a Phase 1/2, open-label, Safety and Efficacy, Tolerability, Anti-Tumor Effects, Systemic Exposure, and Device Technical Effects of PRV211 (Intraoperative Cisplatin System) in subjects with T2-T3 oral squamous cell carcinoma (SCC) amenable to surgery. Study Design: This study will enroll up to 40 subjects. An interim analysis will take place to evaluate safety and efficacy results and the addition of a second arm (see interim analysis section for further detail). In this study both safety and efficacy will be evaluated. All subjects will be monitored for possible DLTs. For the purpose of dose selection, tolerable dose is defined as a dose where fewer than 33% of subjects being evaluated within the safety population present with dose-limiting toxicities (DLTs). Effective dose is determined based on the evaluable population as described in the Statistical Methods section. The study is described below: Up to 15 subjects will be enrolled for stage 1 and undergo 1 PRV211 treatment application during standard of care tumor resection surgery. Each treatment will include permeation enhancer. If 5 or less respond, the dose can be escalated given safety requirements are met. A total of ten (10) PRV211 patches can be applied in this single application during tumor resection surgery. Definition of Response: A subject will be considered to have responded to the treatment if there is no incidence of locoregional recurrence at 3 months post-surgery and/or adjuvant therapy as indicated on positron emission tomography (PET) scan.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date October 2026
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adult subjects, men and women, defined by age =18 years at the time of screening. 2. Pathologically proven and clinically confirmed T2-T3, Nx-N2b, M0 SCC of the lip or oral cavity (anterior 2/3 of the tongue, floor of mouth, lower and upper gingiva, hard palate, and buccal mucosa). 3. Tumor must be amenable to surgical resection. 4. Clinically and/or radiologically measurable tumor. 5. Eastern Collaborative Oncology Group (ECOG) Performance Status of =2. 6. Candidates for standard of care treatment consisting of surgery. 7. Male and female subjects of childbearing potential must agree to use 2 methods of effective contraception from screening and for at least 30 days after the final dose of investigational product. Appropriate birth control is defined as barrier methods with spermicides, oral or parenteral contraceptives and/or intrauterine devices, or naturally or surgically sterile (with documentation in the subject's medical records). Postmenopausal women are defined as presenting at least 12 months' natural spontaneous amenorrhea, or at least 6 weeks following surgical menopause (bilateral oophorectomy). Females of childbearing potential must be non-lactating and have a negative serum hCG within 14 days of treatment initiation. 8. Absence of any serious underlying medical conditions which could impair the ability of the subject to participate in the study. 9. Have a life expectancy of =6 months. 10. Willing and able to provide written informed consent. 11. Able to return to study site for treatment and follow-up visits as defined in the Protocol. Exclusion Criteria: 1. Concurrent documented malignancy, except for localized SCCs of the skin 2. Exposure to any investigational agent within 3 months prior to Screening 3. Known allergy or hypersensitivity to platinum-containing agents, or known intolerance to a prior platinum-containing agent, or to any of the excipients, which, in the judgement of the physician will preclude re-exposure to platinum-containing agent 4. Active, uncontrolled infection requiring systemic therapy, such as but not limited to HIV, Hepatitis B or C 5. Uncontrolled intercurrent illness that would risk subject safety, interfere with the objectives of the Protocol, or limit subject compliance with study requirements, as determined by the Investigator 6. Known or suspected pregnancy, planned pregnancy, or lactation 7. Any medical or psychiatric condition that may compromise the ability to give written informed consent Test Product, Dose and Mode of Administration: PRV211 (Cisplatin Intraoperative Treatment) consists of:

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PRV211 (Intraoperative Cisplatin System)
PRV211 system is comprised of two parts, a liquid permeation enhancer (PE) and cisplatin patch. The permeation is brushed onto the resected tumor bed and after 5 minutes the patch can be applied directly over the same area. Apply up to 2 layers of the PRV211 system to the tumor bed post-resection. The duration of the PRV211 treatment takes approximately 10-20 minutes and then the surgeon can continue as planned with the rest of the standard of care procedure. The proposed starting dose is 0.5 mg/cm2 of cisplatin on the tumor bed. This approach can be safe and effective in preventing locoregional recurrence after surgery and eliminating high-risk factors for local recurrence, such as dysplasia at the margins.

Locations

Country Name City State
United States Advanced ENT and Allergy Louisville Kentucky

Sponsors (2)

Lead Sponsor Collaborator
Privo Technologies National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Endpoint Locoregional Recurrence 3 months post-surgery or completion of adjuvant therapy
See also
  Status Clinical Trial Phase
Recruiting NCT04543266 - Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning
Not yet recruiting NCT06438939 - NBI for Early Diagnosis of OPMD/OSCC N/A
Recruiting NCT05024383 - Dissecting the Heterogeneity of Oral Cancer Pain N/A
Recruiting NCT06031337 - Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
Not yet recruiting NCT06174428 - Validity of Viome's Oral/Throat Cancer Test
Recruiting NCT05098119 - Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) Phase 2
Recruiting NCT05069857 - Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients Phase 2
Not yet recruiting NCT03619304 - Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line N/A
Active, not recruiting NCT01772706 - Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer N/A
Recruiting NCT05125055 - Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC Phase 2/Phase 3
Not yet recruiting NCT06055868 - People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
Not yet recruiting NCT06130007 - A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma. Phase 2
Recruiting NCT05798793 - Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma Phase 3
Recruiting NCT02739204 - Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma Phase 2
Completed NCT05708209 - The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124
Recruiting NCT05862168 - Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma :A Single-arm, Prospective, Phase II Trial Phase 2
Recruiting NCT05451303 - Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
Recruiting NCT05902455 - Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis
Not yet recruiting NCT05803915 - Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy Phase 2
Recruiting NCT05791149 - Epigenetic Biomarkers in the Saliva for the Diagnosis of Squamous Cells Carcinoma of the Oral Cavity N/A